Back to results
US 2022/0090132 A1Published application
Car t cell methods and constructs
AssigneeAbintus Bio, Inc.
InventorsDouglas J. Jolly, Joan M. Robbins, Amy H. Lin, Derek G. Ostertag, Cornelia Bentley, Sophie Viaud
Life of this patent
Estimating the term…
Abstract
The disclosure provides non-replicating viral vectors (RNV) for adoptive cell therapy. The RNVs can deliver chimeric antigen receptors to immune cells (e.g., T-Cells) in vivo.
Claims49
A pharmaceutical composition for administration to a subject, the pharmaceutical composition comprising:
- a non-replicating viral vector containing a heterologous polynucleotide encoding a chimeric antigen receptor (CAR) or CAR-like product having an immune activating effect
- wherein the non-replicating viral vector transduces or integrates into blood cells of the subject in vivo.
8-9. (canceled)
(canceled)
(canceled)
A non-replicating viral vector comprising:
- an envelope comprising envelope proteins and lipid membrane;
- a nucleic acid contained within the envelope, the nucleic acid comprising a sequence from 5′ to 3′ comprising:
- SEQ ID NO:12 from nucleotide 1 to 1050 or a sequence that is at least 85% identical thereto;
- an RNA sequence encoding a chimeric antigen receptor (CAR);
- and
- SEQ ID NO:12 from nucleotide 1101 to 1662 or a sequence that is at least 85% identical thereto,
- wherein the RNV can infect dividing cells and wherein the RNA sequence encoding the chimeric antigen receptor is integrated into the dividing cell.
4 more elements
Dependencies are inferred from the claim text.